Aigen Investment Management LP Grows Stake in Teleflex Incorporated (NYSE:TFX)

Aigen Investment Management LP boosted its position in shares of Teleflex Incorporated (NYSE:TFX) by 33.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,883 shares of the medical technology company’s stock after purchasing an additional 718 shares during the quarter. Aigen Investment Management LP’s holdings in Teleflex were worth $713,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Texas Permanent School Fund Corp grew its stake in Teleflex by 1.6% in the 1st quarter. Texas Permanent School Fund Corp now owns 9,714 shares of the medical technology company’s stock valued at $2,197,000 after acquiring an additional 152 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its position in shares of Teleflex by 10.7% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 1,648 shares of the medical technology company’s stock valued at $373,000 after purchasing an additional 159 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Teleflex during the 1st quarter worth approximately $537,000. SG Americas Securities LLC raised its position in shares of Teleflex by 415.3% during the 1st quarter. SG Americas Securities LLC now owns 6,920 shares of the medical technology company’s stock worth $1,565,000 after purchasing an additional 5,577 shares during the last quarter. Finally, Sei Investments Co. lifted its stake in Teleflex by 22.0% in the 1st quarter. Sei Investments Co. now owns 23,012 shares of the medical technology company’s stock valued at $5,205,000 after buying an additional 4,156 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Trading Down 0.8 %

Shares of TFX stock opened at $193.98 on Thursday. Teleflex Incorporated has a 1-year low of $193.49 and a 1-year high of $257.85. The firm’s 50-day simple moving average is $233.46 and its 200-day simple moving average is $223.73. The firm has a market cap of $9.01 billion, a P/E ratio of 38.56, a PEG ratio of 2.00 and a beta of 1.18. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.42 and a quick ratio of 1.39.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, beating analysts’ consensus estimates of $3.38 by $0.11. Teleflex had a net margin of 7.85% and a return on equity of 14.19%. The company had revenue of $764.40 million for the quarter, compared to analyst estimates of $768.68 million. During the same quarter last year, the business earned $3.64 EPS. Teleflex’s revenue for the quarter was up 2.4% on a year-over-year basis. As a group, equities analysts forecast that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.34 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $1.36 annualized dividend and a yield of 0.70%. Teleflex’s dividend payout ratio is presently 27.04%.

Insider Transactions at Teleflex

In related news, Director Stuart A. Randle sold 2,674 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $238.93, for a total transaction of $638,898.82. Following the completion of the sale, the director now owns 5,496 shares of the company’s stock, valued at approximately $1,313,159.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Mizuho dropped their price target on Teleflex from $275.00 to $250.00 and set a “neutral” rating for the company in a research report on Friday, November 1st. StockNews.com raised shares of Teleflex from a “hold” rating to a “buy” rating in a research note on Tuesday. Stephens upped their target price on shares of Teleflex from $275.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Royal Bank of Canada lowered their price target on shares of Teleflex from $275.00 to $245.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Truist Financial reissued a “hold” rating and set a $227.00 price objective (down previously from $255.00) on shares of Teleflex in a research note on Monday, November 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $259.25.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.